Third Harmonic Bio, Inc. is a high-risk pharmaceutical company based in the United States of America. Specializing in the development of innovative treatments for inflammatory diseases, including dermal, respiratory, and gastrointestinal conditions. Their product candidates, THB001 and THB335, are oral small-molecule inhibitors targeting mast cell function and are designed to transform the treatment of various inflammatory conditions. With a strong focus on sustainability and governance, Third Harmonic Bio, Inc. has an ESG score of 34.1.